August 25th, 2016|
Otsuka America Pharmaceutical, Inc. © has finally made changes to the label for the prescription drug Abilify® at the instruction of the FDA in the warning posted on May 3, 2016.
The new detailed label warning suggests that “patients can experience intense urges, particularly for gambling, and the inability to control these urges while taking aripiprazole. Other compulsive urges, reported less frequently include: sexual urges, shopping, eating or binge eating, and other impulsive or compulsive behaviors.” Read full label here.
Abilify is an anti-psychotic commonly prescribed to treat mental disorders, such as bipolar disorder, schizophrenia, and severe depression. Many of these patients are often times susceptible to the side effects listed in the new warning because they may have a difficult time linking the compulsive behaviors to the medication. Therefore, it is incumbent on the manufacturers of Abilify to help patients and doctors identify the link between this side effect and Abilify usage. This is highlighted in the warning where it says that “patients may not recognize such behaviors as abnormal,” and the company “counsels physicians to ask about such behaviors and recommends discontinuation or dose reduction if behaviors arise.”
If you or someone you love suffered from compulsive gambling after taking Abilify, you may be entitled to compensation for your losses. Contact our drug injury lawyers today for a free consultation of your claim. We’ll work to hold the manufacturers accountable for what your family has been through.
Do not stop taking any medication without consulting your doctor